New 52 Week Low Today

Cadrenal Therapeutics Inc CVKD:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 01/28/23 EST
2.63quote price arrow up+0.01 (+0.38%)
Volume
2,693
Close
2.62quote price arrow down-0.22 (-7.75%)
Volume
112,109
52 week range
2.60 - 6.75
Loading...
  • Open2.87
  • Day High2.90
  • Day Low2.60
  • Prev Close2.84
  • 52 Week High6.75
  • 52 Week High Date01/20/23
  • 52 Week Low2.60
  • 52 Week Low Date01/27/23

Key Stats

  • Market Cap30.483M
  • Shares Out11.63M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open2.87
  • Day High2.90
  • Day Low2.60
  • Prev Close2.84
  • 52 Week High6.75
  • 52 Week High Date01/20/23
  • 52 Week Low2.60
  • 52 Week Low Date01/27/23
  • Market Cap30.483M
  • Shares Out11.63M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-63.35%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Cadrenal Therapeutics Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Cadrenal Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (ESRD), and atrial fibrillation (irregular heartbeat) (AFib). The Company’s lead drug candidate, tecarfarin, is an anticoagulant that uses a drug design process which targets a different pathway...
Quang Pham
Chairman of the Board, Chief Executive Officer
Matthew Szot CPA
Chief Financial Officer
Address
822 A1a North, Suite 320
Ponte Vedra, FL
32082
United States